Clinical trials: CCUS Clonal Cytopenia of Undetermined Significance
CCUS Clonal Cytopenia of Undetermined Significance, Anemia
Luspatercept for Clonal Cytopenias of Uncertain Significance
The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS).
- Conditions
- CCUS Clonal Cytopenia of Undetermined Significance, Anemia, Leukopenia, Thrombocytopenia
- Trial name
- NCT06788691
- Testing
- Luspatercept
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Weill Medical College of Cornell University
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-1
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies
The primary purpose of this multi-centre, randomized, placebo-controlled, double-blind phase II study is to investigate if oral vitamin C may change the biology of low-risk myeloid malignancies; i.e., clonal cytopenia of…
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-1, Cytopenia
- Trial name
- EVITA (NCT03682029)
- Testing
- Vitamin C (ascorbic acid)
- Where
- 5 sites in United States, Denmark
- Volunteers
- 109 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT06295965
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- University of Washington
Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance
A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance
Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts.
- Trial name
- NCT05102370
- Testing
- Enasidenib
- Where
- 12 sites in United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center